At 2.7% CAGR, Europe Feed Anticoccidials Market is Projected to be Worth US$ 290.93 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the Europe feed anticoccidials market was valued at US$ 234.76 million in 2023 and is expected to reach US$ 290.93 million by 2031, registering a CAGR of 2.7% from 2023 to 2031. Introduction of non-ionophores in animal feed and adoption of bio shuttle program for managing coccidiosis are among the critical factors attributed to the Europe feed anticoccidials market expansion.

Ionophores have some degree of antibacterial activity and fit the classical definition of an antibiotic. All ionophores are approved for broiler chicken production, but not all are approved or safe for turkeys. Salinomycin and narasin are quite toxic for turkeys and equines. As ionophores are antibiotics, they should not be used continuously but instead rotated with different anticoccidials. Moreover, there are stringent regulations on using antibiotics in feed as an additive. Thus, manufacturers are developing different anticoccidials that cannot be called antibiotics.

Non-ionophores are compounds produced by chemical synthesis; thus, they fall under the category of chemical anticoccidials. They destroy coccidia by cidal activity or suppress coccidia by static activity. They have no known antibacterial activity; hence, they are not considered as an antibiotic. Non-ionophores are products containing nicarbazin, zoalene, amprolium, clopidol, decoquinate, robenidine and diclazuril. EW Nutrition-an agribusiness company that creates solutions that bring reliable benefits with reduced need for antibiotics, especially in feed-has developed non-ionophores for animal feed. Owing to all these factors, livestock farmers concerned about using antibiotics in animal feed can opt for non-ionophore anticoccidials. Therefore, the introduction of non-ionophore in animal feed is expected to offer lucrative opportunities for the feed anticoccidials market during the forecast period.

On the contrary, stringent regulation on use of antibiotics in animal feed hamper the growth of Europe feed anticoccidials market.

Based on type, the Europe feed anticoccidials market is segmented into ionophore, chemical anticoccidials, and chemical-ionophores. The ionophore segment held 45.2% market share in 2023, amassing US$ 106.13 million. It is projected to garner US$ 127.53 million by 2031 to register 2.3% CAGR during 2023-2031.

In terms of form, the Europe feed anticoccidials market is bifurcated into dry and liquid. The dry segment held 91.9% share of Europe feed anticoccidials market in 2023, amassing US$ 215.77 million. It is projected to garner US$ 266.37 million by 2031 to expand at 2.7% CAGR during 2023-2031.

Based on livestock, the Europe feed anticoccidials market is segmented into poultry, ruminants, swine, and others. The poultry segment held 80.7% market share in 2023, amassing US$ 189.50 million. It is projected to garner US$ 232.59 million by 2031 to register 2.6% CAGR during 2023-2031.

Based on country, the Europe feed anticoccidials market has been categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that the Rest of Europe captured 46.6% share of Europe feed anticoccidials market in 2023. It was assessed at US$ 109.35 million in 2023 and is likely to hit US$ 128.39 million by 2031, exhibiting a CAGR of 2.0% during 2023-2031.

Key players operating in the Europe feed anticoccidials market are Phibro Animal Health Corp, Zoetis Inc, Kemin Industries Inc, Elanco Animal Health Inc, Huvepharma EOOD, Impextraco NV, and Virbac SA., among others.

• In April 2024, Zoetis and Phibro Animal Health acquired Zoetis' medicated feed additive product portfolio, water soluble products, and related assets for $350 million. The acquisition, which generated $400 million in revenue in 2023, includes over 37 product lines and six manufacturing sites. The transaction is expected to be completed in the second half of 2024. Over 300 Zoetis colleagues are expected to transition to Phibro Animal Health.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com